3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
7
Thoracic
2
Head & Neck
1
CNS
1
Conditions
Squamous Cell Carcinoma of Head and Neck
110
Head and Neck Neoplasms
97
Nasopharyngeal Carcinoma
36
Carcinoma, Non-Small-Cell Lung
21
Salivary Gland Neoplasms
17
Carcinoma, Squamous Cell
14
Laryngeal Neoplasms
12
Nasopharyngeal Neoplasms
10
Melanoma
10
Breast Neoplasms
10
Oropharyngeal Neoplasms
9
Hypopharyngeal Neoplasms
9
Stomach Neoplasms
8
Neoplasms
8
Esthesioneuroblastoma, Olfactory
8
Esophageal Neoplasms
8
Prostatic Neoplasms
7
Ovarian Neoplasms
7
Carcinoma, Renal Cell
7
Urinary Bladder Neoplasms
6
Tongue Neoplasms
6
Small Cell Lung Carcinoma
6
Recurrence
6
Lung Neoplasms
6
Pancreatic Neoplasms
5
Neoplasm Metastasis
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Thyroid Neoplasms
4
Mouth Neoplasms
4
Interventions
pembrolizumab
5
Nivolumab
2
trifluridine tipiracil drug combination
1
tremelimumab
1
trametinib
1
regorafenib
1
niraparib
1
larotrectinib
1
futibatinib
1
durvalumab
1
dostarlimab
1
dabrafenib
1
cemiplimab
1
TAS-116
1
Ramucirumab
1
Itraconazole
1
Gemcitabine
1
Fluorouracil
1
Docetaxel
1
Clinical Trials, Phase II as Topic
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Antibodies
1
4-(2-fluoro-4-((((2-phenylacetyl)amino)thioxomethyl)amino)phenoxy)-7-methoxy-N-methyl-6-quinolinecarboxamide
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
Docetaxel
×
Head & Neck
×
Clear all
NCT05094336
2026-05-28
MTAPESTRY 101
Amgen
Phase 1/2
Active not recruiting
329 enrolled